ImStar Therapeutics Inc. is using new discoveries about the physiopathology of amyotrophic lateral sclerosis to develop small molecules that block a key kinase interaction leading to immune-related neuroinflammation. The company hopes to have preclinical proof-of-concept data by this summer.

Amyotrophic lateral sclerosis (ALS) is a progressive and eventually fatal neurodegenerative disease for which the only approved drug - Rilutek riluzole from Sanofi - has limited efficacy and known side effects.